Icosabutate 是一种口服有效的工程化脂肪酸,也是双重 FFAR1/FFAR4 (GPR40/GPR120) 激动剂(EC50 分别为 10 和 15.5 μM),同时是 PPAR-α 的部分激动剂(EC50 为 208 nM),可抑制花生四烯酸级联并具有抗氧化和抗凋亡 (apoptosis) 活性,可用于非酒精性脂肪性肝炎、代谢功能障碍相关脂肪性肝炎及动脉粥样硬化的研究。
产品编号: MS-T24093 纯度: 97.28% CAS No.: 1253909-57-7 分子式: C24H38O3 分子量: 374.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Icosabutate 是一种口服有效的工程化脂肪酸,也是双重 FFAR1/FFAR4 (GPR40/GPR120) 激动剂(EC50 分别为 10 和 15.5 μM),同时是 PPAR-α 的部分激动剂(EC50 为 208 nM),可抑制花生四烯酸级联并具有抗氧化和抗凋亡 (apoptosis) 活性,可用于非酒精性脂肪性肝炎、代谢功能障碍相关脂肪性肝炎及动脉粥样硬化的研究。

生物实验数据

生物活性 Icosabutate is an orally active engineered fatty acid and a dual FFAR1/FFAR4 (GPR40/GPR120) agonist with EC50 values of 10 and 15.5 μM, respectively, and a partial PPAR-α agonist with an EC50 of 208 nM that inhibits the arachidonic acid cascade and exhibits antioxidant and anti-apoptotic (apoptosis) activities, and can be used for research on nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, and atherosclerosis.
IC50 & Target

IC50: non-HDL-C

体外研究
(In Vitro)

Icosabutate 可在转染细胞系中完全激活人 FFAR4 β-arrestin2 通路,其 EC50 为 15 μM。
Icosabutate 在转染的 HEK293 细胞中激活人源 FFAR1 钙流通路,其 EC50 为 10 μM,最大效能达 90%。
Icosabutate 在转染的 HEK293 细胞中可部分激活人 PPAR-α,其 EC50 为 208 nM,最大效能为 62%。
Icosabutate 可显著抑制 LX-2 肌成纤维细胞的增殖。

体内研究
(In Vivo)

Icosabutate (135 mg/kg;口服;每日一次;持续 5 周) 可改善雄性 ob/ob 小鼠的糖代谢与胰岛素敏感性,使 HOMA-IR 降低 87%,血浆丙氨酸转氨酶水平降低 33%。
Icosabutate (112 mg/kg;口服;每日一次;持续 20 周) 可减轻动脉粥样硬化模型小鼠的微泡性脂肪变性、肝脏炎症、纤维化、脂毒性脂质种类及氧化应激。
Icosabutate (45-135 mg/kg;口服;每日一次;4-8 周) 可剂量依赖性地减轻雄性 ob/ob 小鼠已形成的非酒精性脂肪性肝炎 (NASH) 中的肝脂肪变性、炎症、氧化应激、细胞凋亡及纤维化进展。
Icosabutate (112 mg/kg;口服;每日一次;持续 4 周) 可通过增强肝脏 VLDL 残粒清除率和 LDL-R 介导的胆固醇摄取,使高脂血症小鼠的血浆 TAG 和总胆固醇分别降低 70%和 68%。
Icosabutate (37.5 mg/kg;口服;每日一次;4.5 周,随后 15 mg/kg;口服;每日一次;12.5 周) 可使小鼠的总胆固醇暴露量降低约 29%,并减少动脉粥样硬化病变的形成、严重程度及病变数量。
Icosabutate (135 mg/kg;每日一次;持续 4 周) 给药 4 周后可显著改善肥胖 Zucker 大鼠的血糖控制,并降低其血浆甘油三酯、胆固醇及 AST 水平。

Animal Model: ob/ob mice (male, 6-8 weeks old, genetic type 2 diabetes/insulin resistance model)
Dosage: 135 mg/kg/d
Administration: p.o.; daily; 5 weeks
Result: Significantly reduced blood glucose by 50%, blood hemoglobin A1c by 47%, plasma insulin by 76%, and HOMA-IR by 87% versus control.
Improved glucose tolerance, reducing the oral glucose tolerance test AUC0-120min by 60% versus control.
Significantly reduced plasma alanine aminotransferase by 33% versus control.
Did not affect body weight or plasma adiponectin levels.
Animal Model: APOE*3Leiden.CETP mice (male, 8-15 weeks old, high-fat/cholesterol-fed diet-induced NASH model)
Dosage: 112 mg/kg/d
Administration: p.o.; daily; 20 weeks
Result: Significantly reduced microvesicular steatosis by 35%, hepatocellular hypertrophy by 82%, and hepatic inflammatory cell aggregates by 62% versus control.
Significantly reduced serum amyloid A levels by 68%, hepatic collagen content by 32%, and fibrosis surface area by 26% versus control.
Reduced hepatic concentrations of multiple lipotoxic lipid species including free fatty acids, diacylglycerols, bile acids, arachidonic acid, ceramides, and hydroxyeicosatetraenoic acids.
Decreased hepatic oxidized glutathione (GSSG) while increasing the GSH/GSSG ratio.
Activated regulators involved in lipid metabolism and energy production, and inhibited pro-inflammatory regulators including STAT1 and NFκB complex, as well as down-regulated fibrogenic genes in hepatic stellate cells via transcriptome analysis.
Animal Model: B6.V-Lepob/JRj (ob/ob) (male, 5 weeks old at arrival, NASH model via AMLN diet for 18 weeks with biopsy confirmation of fibrosis stage ≥1 and steatosis score ≥2; separate screening group fed AMLN diet for 15 weeks without biopsy)
Dosage: 45 mg/kg bw/d; 90 mg/kg bw/d; 135 mg/kg bw/d (8-week treatment); 112 mg/kg bw/d (4-week screening study)
Administration: p.o.; daily; 8 weeks (45, 90, 135 mg/kg); p.o.; daily; 4 weeks (112 mg/kg)
Result: Reduced steatosis by 47%.
Reduced hepatic TAG by 17% (45 mg/kg), 35% (90 mg/kg), 40% (135 mg/kg).
Reduced plasma ALT by 32% (90 mg/kg) and 44% (135 mg/kg).
Significantly reduced hepatic galectin-3 content (all doses).
Reduced hepatic col1A1 % area by 27% (90 mg/kg) and total col1A1 by 32% (90 mg/kg) and 23% (135 mg/kg).
Minimized fibrosis progression (90 mg/kg, post-pre biopsy col1A1 change).
Reduced hepatic hydroxyproline (HYP) content in relative and total units (90 mg/kg and 135 mg/kg).
Reduced hepatic α-SMA % area and total content (90 mg/kg and 135 mg/kg).
Reduced post-pre biopsy α-SMA content (135 mg/kg).
Reduced hepatic free fatty acids (FFAs), diacylglycerols (DAG), ceramides, total HETEs by 45% (90 mg/kg) and 51% (135 mg/kg), phosphatidylcholine-arachidonic acid (PC-AA) by 32% (90 mg/kg) and 42% (135 mg/kg), oxidised glutathione (GSSG), and oxidised phospholipids (oxPL) by 31% (90 mg/kg) and 46% (135 mg/kg).
Increased hepatic GSH/GSSG ratio by 84% (135 mg/kg).
Reduced hepatic apoptotic cell numbers by 41% (45 mg/kg), 29% (90 mg/kg), and 44% (135 mg/kg).
Downregulated hepatic mRNA transcripts for genes regulating inflammatory responses (TNF-α, TGF-β1, TGFRβ, CCR2), stellate cell activation, fibrogenesis, and fibrolysis (112 mg/kg).
Animal Model: APOE*3Leiden.CETP transgenic (C57BL/6J background) (male, 7-10 weeks old, hyperlipidaemia model via 4-week run-in on Western-type diet with 0.25% cholesterol)
Dosage: 112 mg/kg bw/d
Administration: p.o.; daily; 4 weeks
Result: Reduced plasma TAG by 70% (P <.001) and total cholesterol by 68% (P <.001); no effect on HDL cholesterol.
Decreased plasma half-life of glycerol tri[3H]oleate by 40% (P =.008) and [14C]cholesteryl oleate by 52% (P =.001); increased hepatic uptake of both lipids.
Increased hepatic LDL-R protein expression compared to controls (P ≤.05).
Reduced hepatic cholesteryl ester content (P ≤.05) and faecal bile acid excretion (P ≤.05); no effect on hepatic free cholesterol, TAG, or faecal neutral sterol excretion.
Upregulated hepatic gene pathways involved in fatty acid metabolism, β-oxidation, and (chole)sterol biosynthetic processes; downregulated pathways including complement activation, arachidonic acid cascade, innate immune response, and acute phase response.
Animal Model: APOE*3Leiden.CETP transgenic (C57BL/6J background) (female, 11-15 weeks old, atherosclerosis model via 4-week run-in on Western-type diet with 0.15% cholesterol)
Dosage: 37.5 mg/kg bw/d (first 4.5 weeks); 15 mg/kg bw/d (final 12.5 weeks)
Administration: p.o.; daily; 17 weeks (37.5 mg/kg for 4.5 weeks, then 15 mg/kg for 12.5 weeks)
Result: Reduced total cholesterol exposure by ~29% compared to controls (P <.001).
Reduced total aortic root lesion area by ~70% compared to controls (P <.001); reduced lesion number per cross section (P ≤.05).
Increased undiseased aortic root segments to 44% (P <.01) and reduced severe type IV-V lesions to 18% compared to controls.
Animal Model: Obese Zucker rats
Dosage: 135 mg/kg
Administration: daily; 4 weeks
Result: Reduced plasma triglycerides from 17.3 mM to 9.6 mM.
Reduced plasma cholesterol from 10.1 mM to 5.4 mM.
Reduced blood glucose from 11.8 mM to 7.2 mM.
Reduced plasma insulin from 17.2 ng/mL to 9.4 ng/mL.
Reduced HbA1c from 7.8% to 5.6%.
Reduced HOMA-IR from 8.7 to 3.0.
Increased plasma LDL-cholesterol from 0.4 mM to 1.5 mM.
Reduced plasma AST from 167.3 U/L to 90.5 U/L.
Caused no significant change in body weight, food intake, plasma VLDL-cholesterol, plasma ALT, or plasma adiponectin.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 374.56
分子式 C24H38O3
CAS No. 1253909-57-7

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.81 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (266.98 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.6698 mL13.3490 mL26.6980 mL66.7450 mL
5 mM0.5340 mL2.6698 mL5.3396 mL13.3490 mL
10 mM0.2670 mL1.3349 mL2.6698 mL6.6745 mL
15 mM0.1780 mL0.8899 mL1.7799 mL4.4497 mL
20 mM0.1335 mL0.6674 mL1.3349 mL3.3372 mL
25 mM0.1068 mL0.5340 mL1.0679 mL2.6698 mL
30 mM0.0890 mL0.4450 mL0.8899 mL2.2248 mL
40 mM0.0667 mL0.3337 mL0.6674 mL1.6686 mL
50 mM0.0534 mL0.2670 mL0.5340 mL1.3349 mL
60 mM0.0445 mL0.2225 mL0.4450 mL1.1124 mL
80 mM0.0334 mL0.1669 mL0.3337 mL0.8343 mL
100 mM0.0267 mL0.1335 mL0.2670 mL0.6674 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础